Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Sam Levy, Randy Scott

Premium

Genomic Health has made a number of changes to its management team and board of directors (see story, this issue).

The company has hired Sam Levy as chief scientific officer, replacing Joffre Baker, who will now serve as senior biology fellow at Genomic Health.

Levy is the director of genomic sciences at Scripps Translational Science Institute and Scripps Genomic Medicine, as well as a professor of molecular and experimental medicine at the Scripps Research Institute.

Previously, Levy served as director and professor in human genomics at the J. Craig Venter Institute, where he was the leading scientist on the first published diploid genome sequence of a human. He holds a BS in molecular biophysics from the University of Leeds and a PhD in cell and computational biology from the University of Bristol.

Randy Scott has stepped down from Genomic Health's board of directors to take on the position of CEO at InVitae, a Genomic Health spinout that will focus on integrating next-generation sequence data into medical practice for patients with rare and common genetic diseases.

Scott was a founder and former CEO of Genomic Health. Prior to founding the company, he served as president and chief scientific officer at Incyte Pharmaceuticals and director of protein biochemistry and senior director of research at Invitron.

He holds a PhD in biochemistry from the University of Kansas and a BS in chemistry from Emporia State University.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.